BioFocus DPI and ZoBio announced today that they have signed a worldwide marketing and sales agreement for ZoBio’s fragment-based NMR technologies. Under the terms of the agreement BioFocus DPI will sell ZoBio’s services either as a standalone offering or in combination with BioFocus DPI’s drug discovery offering.
ZoBio has extensive experience in fragment–based screening using its patented Target Immobilized NMR Screening (TINS) technology. TINS allows rapid screening of drug fragment libraries with high sensitivity using only a few mg of target protein. An additional advantage of TINS screening is that it can be achieved in a few weeks, accelerating the drug discovery process.
“The addition of the ZoBio technology to BioFocus DPI’s offerings will enhance our hit finding capabilities” said Chris Newton, Senior Vice President of BioFocus DPI. “The technology will expand our fragment-based screening obtained through the acquisition of Sareum’s X-ray crystallography”.
”We are pleased that BioFocus has selected ZoBio as a strategic partner for their fragment-based drug discovery services” said Gregg Siegal, CSO of ZoBio. “We feel the combination will offer customers proven, cutting edge technologies to meet their biggest drug discovery challenges.”
About ZoBio ZoBio provides fragment discovery and characterization services to the pharmaceutical and biotech industries using its proprietary Target Immobilized NMR Screening (TINS) platform. TINS, with its unparalleled sensitivity and reliability, has been used to discover highly diverse, efficient ligands for a variety of targets including kinases, protein-protein interactions, viral targets and membrane proteins.
About BioFocus DPI BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, medicinal chemistry, structural biology and ADME/PK services, supported by unique informatics tools. As the service division of Galapagos, BioFocus DPI has over 300 laboratory-based employees in four countries worldwide.
CONTACT
BioFocus DPI Chris Newton, PhD Senior Vice President, BioFocus DPI Tel: +44 1799 533500 chris.newton@glpg.com
ZoBio BV Gregg Siegal Chief Scientific Officer Tel: +31 71 527 4543 gsiegal@zobio.com